Long-Term Follow-Up from the Phase 1/2 MajesTEC-1 trial of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma

home / between-the-lines / long-term-follow-up-from-the-phase-1-2-majestec-1-trial-of-teclistamab

Amrita Y. Krishnan, MD, and Binod Dhakal, MD, review recent data from the MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma and have a discussion on evolving therapeutic practices.

Amrita Y. Krishnan, MD, and Binod Dhakal, MD

EP. 1: The Current Treatment Landscape for Relapsed/Refractory Multiple Myeloma

Amrita Y. Krishnan, MD;Binod Dhakal, MD, MS
June 24th 2024

Amrita Y. Krishnan, MD, and Binod Dhakal, MD, provide an overview of the current treatment landscape in relapsed/refractory multiple myeloma.

Amrita Y. Krishnan, MD, and Binod Dhakal, MD

EP. 2: MajesTEC-1: Efficacy and Safety of Teclistamab

Amrita Y. Krishnan, MD;Binod Dhakal, MD, MS
June 24th 2024

Experts on multiple myeloma review the study design and results from MajesTEC-1, focusing on the efficacy and safety findings, and provide insights on adverse event management practices.